We have become aware of an individual who is falsely representing themselves as a member of the Celerion HR team. Please be cautious when responding to any communication that purports to come from Celerion. All email communication from Celerion will come from an email address appended @celerion.com. No other addresses are legitimate. #hr
Celerion
Pharmaceutical Manufacturing
Lincoln, NE 14,699 followers
Celerion Can Take You from First-In-Human through Proof-of-Concept.
About us
Celerion, a leader in early clinical research, delivers Applied Translational Medicine. Celerion applies our expertise and experience to translating information gained in research discoveries, to knowledge of drug action and effect in humans to support early drug development decisions and the clinical pharmacology labeling of new medicines. With over 50 years of experience and 600 global clinic beds (including 24 in-hospital), Celerion conducts and analyzes First-in-Human, clinical proof-of-concept, cardiovascular safety (TQT, robust QT), ADME and NDA-enabling clinical pharmacology studies. Celerion provides expertise on modeling and simulation, study design, medical writing (protocols and reports), clinical data sciences, biostatistics, and PK/PD analysis as well as small and large molecule bioanalytical assays through clinical drug development. Regulatory, drug development and program management complement Celerion’s service offerings. Our operations are strategically located in: Lincoln, Nebraska (Corporate Headquarters) Philadelphia, Pennsylvania Phoenix, Arizona Belfast, Northern Ireland,UK Zurich, Switzerland Vienna, Austria Richmond, Virginia Montreal, Quebec, Canada For more information, visit: www.celerion.com
- Website
-
http://www.celerion.com
External link for Celerion
- Industry
- Pharmaceutical Manufacturing
- Company size
- 1,001-5,000 employees
- Headquarters
- Lincoln, NE
- Type
- Privately Held
- Founded
- 2010
- Specialties
- Applied Translational Medicine, Global Clinical Research (Phase I and II, NDA-enabling clinical pharmacology), Data Management and Biometrics, Global Bioanalytical Services (discovery through late phase), Drug Development Services, and Global Clinical Development
Locations
Employees at Celerion
Updates
-
There's still time to register to attend a special talk on 5/29 at 11:15 a.m. ET, hosted by AAPS and featuring Dr. Johannes Stanta, Ph.D., from Celerion. Discover groundbreaking developments in gene therapy through Dr. Stanta's presentation on vector shedding assays. Learn about a new sensitive method to detect AAV8 vector shedding in biological samples like blood, plasma, and more. Don't miss out on enhancing your understanding of these pivotal advancements! Enroll now: https://lnkd.in/dvq8iZ79 #GeneTherapy #Biotech #AAPS #HealthcareScience
-
Celerion's recent findings in the field of pharmacokinetics are more than just numbers—they're a testament to the power of predictive science. By closely examining the excretion profiles of drugs in animal models, we've unlocked a deeper understanding of human responses, paving the way for more targeted and effective therapies. Read now -> https://lnkd.in/eAhVkqX3 #DrugDevelopment #ADMEStudies #Pharmacokinetics #DrugExcretion
-
Celerion’s Regulatory Affairs experts have extensive IND authorship, submission, and management experience to relieve you of this vital yet complex and labor-intensive process. Check out our full regulatory & scientific affairs support services: https://lnkd.in/e-sCYGCk #RegulatoryExcellence #PharmaRegulations #RegulatoryAffairs #DrugDevelopment
-
Happy Clinical Trials Day! Join us in raising awareness about clinical trials and honoring clinical research professionals worldwide. Learn more about Celerion: https://www.celerion.com/ #ClinicalTrials #ClinicalTrialsDay #ClinicalResearch
-
Celerion is hiring for multiple locations! Please check it out. #clinicalresearchjobs #nowhiring #celerion
-
In this webinar, our team of ADME experts review the essential information you need to know before conducting a mass balance study. Watch here: https://lnkd.in/dj5MD8i #ADMEExperts #ClinicalStudies #MultiStudyCapacity #ClinicalInnovation
-
In a dedicated TQT study, 12-lead ECG digital recordings are collected following therapeutic and supratherapeutic dose administrations of a study drug. Typically, these are randomized, placebo- and positive-controlled, 4-arm clinical trials. In this tutorial, we describe situations when a standalone TQT study is recommended, which can depend on the study drug’s mechanism of action, its drug class as well as PK and safety profile. Read the CPT tutorial: Should You Run a Dedicated TQT Study? Sponsor and Regulatory Considerations on Substitution Pathways to Assess QT Liability https://lnkd.in/eeaVxPvT #TQTwaiver #TQTsubstitution #ECGcorelab
-
The electrocardiogram’s QT interval occupies a pivotal role in early drug development and has been the focus of clinicians for over 50 years as a biomarker of ventricular repolarization. Now, drug sponsors have options when it comes to proarrhythmic risk assessment of a new chemical entity. In our recent CPT tutorial, we described the regulatory framework for integrated arrhythmia risk prediction models for TQT substitution pathways (ICH E14/S7B Q&A 5.1 and 6.1), delineate potential reasons why a TQT substitution request may be rejected and discuss when a standalone TQT is recommended. #TQTwaiver #TQTsubstitution #ECGcorelab
-
The electrocardiogram’s QT interval occupies a pivotal role in early drug development and has been the focus of clinicians for over 50 years as a biomarker of ventricular repolarization. Now, drug sponsors have options when it comes to proarrhythmic risk assessment of a new chemical entity. In our recent CPT tutorial, we described the regulatory framework for integrated arrhythmia risk prediction models for TQT substitution pathways (ICH E14/S7B Q&A 5.1 and 6.1), delineate potential reasons why a TQT substitution request may be rejected and discuss when a standalone TQT is recommended. #TQTwaiver #TQTsubstitution #ECGcorelab